Immix Biopharma Inc (IMMX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.91+0.58%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IMMX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue development of NXC-201 in the NEXICART-2 Phase 2 trial with planned BLA submission and commercial launch following topline results.
Stated as a priority in 3 of last 3 quarters. Management expects topline results from the NEXICART-2 Phase 2 trial in Q3 2026, with a planned BLA submission and commercial launch thereafter. The trial is a 45-patient registrational study. This priority is actively progressing with scheduled data updates and regulatory milestones.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Next NEXICART-2 update expected late September 2026.”
“Topline results expected in Q3 2026, followed by BLA submission and planned commercial launch.”
“NEXICART-2 is a multi-site U.S. Phase 2 clinical trial with a registrational design.”
Manage operating expenses and cash flow to sustain operations through clinical development.
Stated as a priority in 6 of last 6 quarters. Operating income worsened from -$4.7M in 2025-Q1 to -$12.5M in 2026-Q2, and cash from operations declined from -$1.7M to -$11.7M over the same period. Despite management focus, operating losses and cash burn have increased, indicating limited progress in controlling expenses.
“Operating income was negative $12.5 million; cash from operations negative $11.7 million.”
“Operating income negative $10.8 million; cash from operations negative $9.8 million.”
“Operating income negative $10.9 million; cash from operations negative $11.0 million.”
“Operating income negative $7.7 million; cash from operations negative $5.9 million.”
“Operating income negative $6.7 million; cash from operations negative $5.3 million.”
“Operating income negative $4.7 million; cash from operations negative $1.7 million.”
Secure financing to support clinical development and operations through mid-2028.
Newly stated in 2026-Q2. The company priced a $150 million underwritten offering in May 2026 to fund NXC-201 development and general corporate purposes, aiming to sustain operations into mid-2028. This capital raise aligns with the stated funding needs for ongoing clinical development.
“Announced pricing of $150 million underwritten offering to fund development and operations into mid-2028.”
Over the trailing year it converted 0.72x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
8 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.